公开(公告)号：US11925631B2

公开(公告)日：2024-03-12

申请号：US17331900

申请日：2021-05-27

Applicant: Gilead Sciences, Inc.

Inventor： Gayatri Balan ,  Mark J. Bartlett ,  Jayaraman Chandrasekhar ,  Julian A. Codelli ,  John H. Conway ,  Jennifer L. Cosman ,  Rao V. Kalla ,  Musong Kim ,  Seung H. Lee ,  Jennifer R. Lo ,  Jennifer A. Loyer-Drew ,  Scott A. Mitchell ,  Thao D. Perry ,  Gary B. Phillips ,  Patrick J. Salvo ,  Joshua J. Van Veldhuizen ,  Suet C. Yeung ,  Jeff Zablocki

IPC: A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5386 ,  C07D471/04 ,  C07D519/00 ,  C12Q1/00

CPC classification number: A61K31/4545 ,  A61K31/444 ,  A61K31/5386 ,  C07D471/04 ,  C07D519/00

Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

公开(公告)号：US11897878B2

公开(公告)日：2024-02-13

申请号：US17522628

申请日：2021-11-09

Applicant: Gilead Sciences, Inc.

Inventor： Gayatri Balan ,  Mark J. Bartlett ,  Jayaraman Chandrasekhar ,  Julian A. Codelli ,  John H. Conway ,  Jennifer L Cosman ,  Rao V. Kalla ,  Zachary A. Kasun ,  Musong Kim ,  Seung H. Lee ,  Jennifer R. Lo ,  Jennifer A. Loyer-Drew ,  Scott A. Mitchell ,  Thao D. Perry ,  Gary B. Phillips ,  Patrick J. Salvo ,  Sundaramoorthi Swaminathan ,  Joshua J. Van Veldhuizen ,  Suet C Yeung ,  Jeff Zablocki

IPC: C07D471/04 ,  A61K31/437 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

公开(公告)号：US11124487B2

公开(公告)日：2021-09-21

申请号：US16441339

申请日：2019-06-14

Applicant: GILEAD SCIENCES, INC.

Inventor： Gregory Chin ,  Richard L. Mackman ,  Michael R. Mish ,  Jeff Zablocki

IPC: C07D239/95 ,  C07D487/04 ,  C07D471/04 ,  C07D495/04 ,  A61K31/517 ,  A61K31/519 ,  A61P35/00 ,  A61P31/18 ,  A61K45/06

Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.

公开(公告)号：US11071730B2

公开(公告)日：2021-07-27

申请号：US16668732

申请日：2019-10-30

Applicant: Gilead Sciences, Inc.

Inventor： Gayatri Balan ,  Mark J. Bartlett ,  Jayaraman Chandrasekhar ,  Julian A. Codelli ,  John H. Conway ,  Jennifer L. Cosman ,  Rao V. Kalla ,  Musong Kim ,  Seung H. Lee ,  Jennifer R. Lo ,  Jennifer A. Loyer-Drew ,  Scott A. Mitchell ,  Thao D. Perry ,  Gary B. Phillips ,  Patrick J. Salvo ,  Joshua J. Van Veldhuizen ,  Suet C. Yeung ,  Jeff Zablocki

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/5386 ,  C07D519/00

Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

公开(公告)号：US20210115037A1

公开(公告)日：2021-04-22

申请号：US16669346

申请日：2019-10-30

Applicant: Gilead Sciences, Inc.

Inventor： Gayatri Balan ,  Mark J. Bartlett ,  Jayaraman Chandrasekhar ,  Julian A. Codelli ,  John H. Conway ,  Jennifer L. Cosman ,  Rao V. Kalla ,  Zachary A. Kasun ,  Musong Kim ,  Seung H. Lee ,  Jennifer R. Lo ,  Jennifer A. Loyer-Drew ,  Scott A. Mitchell ,  Thao D. Perry ,  Gary B. Phillips ,  Patrick J. Salvo ,  Sundaramoorthi Swaminathan ,  Joshua J. Van Veldhuizen ,  Suet C. Yeung ,  Jeff Zablocki

IPC: C07D471/04 ,  C07D519/00

Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

公开(公告)号：US20200017451A1

公开(公告)日：2020-01-16

申请号：US16441339

申请日：2019-06-14

Applicant: GILEAD SCIENCES, INC.

Inventor： Gregory Chin ,  Richard L. Mackman ,  Michael R. Mish ,  Jeff Zablocki

IPC: C07D239/95 ,  C07D495/04 ,  C07D487/04 ,  C07D471/04 ,  A61K45/06 ,  A61K31/519 ,  A61K31/517 ,  A61P35/00 ,  A61P31/18

Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.

公开(公告)号：US20180282316A1

公开(公告)日：2018-10-04

申请号：US16001832

申请日：2018-06-06

Applicant: Gilead Sciences, Inc.

Inventor： Evangelos Aktoudianakis ,  Gregory Chin ,  Britton Kenneth Corkey ,  Jinfa Du ,  Kristyna M. Elbel ,  Robert H. Jiang ,  Tetsuya Kobayashi ,  Rick Andrew Lee ,  Ruben Martinez ,  Samuel E. Metobo ,  Michael R. Mish ,  Manuel Munoz ,  Sophia L. Shevick ,  David Sperandio ,  Hai Yang ,  Jeff Zablocki

IPC: C07D413/04 ,  C07D453/02 ,  C07D417/14 ,  C07D471/04 ,  C07D413/14

Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.

公开(公告)号：US10072001B2

公开(公告)日：2018-09-11

申请号：US14728562

申请日：2015-06-02

Applicant: Gilead Sciences, Inc.

Inventor： Zhimin Du ,  Juan Arnaldo Guerrero ,  Joshua Aaron Kaplan ,  John Edward Knox, Jr. ,  Devan Naduthambi ,  Barton W. Phillips ,  Chandrasekar Venkataramani ,  Peiyuan Wang ,  William J. Watkins ,  Jeff Zablocki

IPC: C07D471/04 ,  C07D487/04 ,  C07D519/00 ,  C07D473/00

CPC classification number: C07D471/04 ,  C07D473/00 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:

公开(公告)号：US09920018B2

公开(公告)日：2018-03-20

申请号：US15372077

申请日：2016-12-07

Applicant: Gilead Sciences, Inc.

Inventor： Michael Graupe ,  Yafan Lu ,  Jeff Zablocki

IPC: C07D261/20 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D417/12

CPC classification number: C07D261/20 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04

Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R2, R3, R4, p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

公开(公告)号：US09676760B2

公开(公告)日：2017-06-13

申请号：US15152231

申请日：2016-05-11

Applicant: Gilead Sciences, Inc.

Inventor： Britton Kenneth Corkey ,  Elfatih Elzein ,  Michael Graupe ,  Juan Guerrero ,  Robert H. Jiang ,  Rao V. Kalla ,  Dmitry Koltun ,  Xiaofen Li ,  Ruben Martinez ,  Eric Q. Parkhill ,  Thao Perry ,  Chandrasekar Venkataramani ,  Jeff Zablocki

IPC: C07D413/06 ,  A61K31/553 ,  A61K31/5513 ,  C07D267/08 ,  C07D243/24 ,  C07D267/14 ,  C07D291/08 ,  C07D403/06 ,  C07D413/12 ,  C07D413/14 ,  C07D419/06 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D243/14 ,  C07B59/00 ,  C07D413/04 ,  C07D417/14

CPC classification number: C07D413/06 ,  A61K31/5513 ,  A61K31/553 ,  C07B59/002 ,  C07B2200/05 ,  C07D243/14 ,  C07D243/24 ,  C07D267/08 ,  C07D267/14 ,  C07D291/08 ,  C07D403/06 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D419/06 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04

Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z1, Z2, Z3, Z4, X, Y, R2, R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.